1. Ningde Times : Credit Rating Upgrading of Corporate Entities and Bonds

Ningde Times (300750) announced that S & P raised the long-term principal credit rating of Ningde Times and the long-term debt rating of senior unsecured bonds guaranteed by Ningde Times from "BBB +" to "A-", with a rating outlook of "stable". S & P believes that "Ningde Times will maintain its global leadership in the battery industry. As business growth drives higher profits, the cash flow from expansion will be sufficient to cover its capital expenditures. The company should be able to maintain a net cash position over the next 24 months".

2, China test navigation : Ningbo yaoda investment plans to increase its stake in the company with 0.12 billion yuan -0.2 billion yuan

China Test Navigation (300627) announced that Ningbo Yao Da Investment Partnership (Limited Partnership) (hereinafter referred to as "Ningbo Yao Da Investment"), a concerted action person of Zhao Yanping, the controlling shareholder and actual controller of the Company, intends to be within 6 months from the date of this announcement (but will not increase its holdings during the window period), increase the company's shares with its own funds or self-raised funds through methods permitted by the Shenzhen Stock Exchange (including but not limited to centralized bidding and block transactions, etc.), and the total amount of the proposed increase shall not be less than 0.12 billion yuan and not more than 0.2 billion yuan.

3, poly development : in April, the contracted amount of 33.024 billion yuan decreased by 20.8 year on year

Poly Development (600048) announced that in April, the company realized a contracted area of 1.8665 million square meters, a year-on-year decrease of 27.33; the contracted amount was 33.024 billion yuan, a year-on-year decrease of 20.8. From January to April, the company achieved a contracted area of 5.5353 million square meters, a year-on-year decrease of 37.64; the contracted amount was 96.008 billion yuan, a year-on-year decrease of 38.39.

4, azure biology : only one synthetic biology technology innovation laboratory is not qualified for industrialization

azure biology (603739) disclosed the announcement of serious abnormal fluctuations in stock trading. recently, the company paid attention to the network and some media released relevant reports on "synthetic biology. The company's main business is the research and development, production and sales of enzyme preparations, microecological preparations and animal health products. The company has only set up one synthetic biotechnology innovation laboratory in the field of synthetic biology, which is mainly used to develop functional proteins for feed and sweeteners for food. However, the laboratory has few R & D projects, small investment amount and few professional personnel allocation. At present, it is still in the early stage of strain laboratory research and development, and there is still a big gap between large-scale amplification and industrialization conditions. The production of synthetic biology products involves separation, purification and other production processes, and the purification process is difficult, the company does not currently have the process, to be further developed. At the same time, the future of the product may also involve registration and regulatory approval, product selection and marketing, etc., the cycle is longer, the difficulty is greater, and there is significant uncertainty in commercialization. It is expected that it will not have a significant impact on the company's operations for a long time. In addition, the company is not involved in research and development in other areas of synthetic biology.

5, huakang medical : pre-bid 81.3689 million yuan Chongqing fourth people's hospital science city hospital construction project

Huakang Medical (301235) announced that the company recently participated in the bidding for the "Chongqing Fourth People's Hospital Science City District Construction Project (Phase I) Medical Special Project" project. The tenderers are Chongqing Fourth People's Hospital, Chongqing Urban Construction Development Co., Ltd. Bid price: 81.3689 million yuan, construction period: 180 calendar days.

6, robot : subsidiary Xinsong semiconductor plans to increase capital and expand shares to introduce war investment

Robot (300024) announced that Xinsong Semiconductor, a wholly-owned subsidiary, introduced strategic investors to increase capital and shares through public listing in Beijing property rights exchange. Nine strategic investors, including Beijing Integrated Circuit equipment Industry Investment M & A Fund (Limited Partnership), National Integrated Circuit Industry Investment Fund Phase II Co., Ltd., and Zhongwei Semiconductor (Shanghai) Co., Ltd., increased capital to Xinsong Semiconductor by participating in this public listing, with a total capital contribution of 0.4 billion yuan to obtain the subject company's new registered capital of 80 million yuan.

7. Zhongyuan Concord : There are no significant changes in the current daily operation and external environment

Zhongyuan Concord (600645) issued an announcement on abnormal fluctuations in stock trading. The deviation of the daily closing price increase of the company's stock on May 7, May 8 and May 9, 2024 reached the ''Shanghai Stock Exchange Trading The deviation of the daily closing price increase for three consecutive trading days stipulated in the Rules has reached 20%, which is an abnormal fluctuation in stock trading. After self-examination, the company's daily operation and external environment have not changed significantly, and there is no material information that should be disclosed but not disclosed.

8. Jimin Medical : The research and development of stem cell drugs in Boao International Hospital under the company is currently in the preclinical stage

Jimin Medical (603222) issued a notice on stock trading risk tips. The current stem cell drug research and development pipeline of Boao International Hospital under the company mainly includes adipose mesenchymal stem cells (ADSC) for the treatment of retinitis pigmentosa (RP), adipose mesenchymal stem cells (ADSC) for the treatment of type 2 diabetes mellitus (T2DM), adipose mesenchymal stem cells (ADSC) for the treatment of chronic obstructive pulmonary disease (COPD), but in preclinical stage, the project is very early. The research and development cycle of innovative drugs is long, with many links and high risks. From development, clinical trials, approval to production, it is easily affected by many factors such as technology, approval, policy and so on. There are many uncertainties in the follow-up research and development.

9, SMIC : it is estimated that the revenue in the second quarter will increase by 5% ~ 7% month on month, and the gross profit rate will increase by 9% ~ 11%

SMIC (688981) said in its financial report that in the second quarter, some customers' demand for early delivery continued, and the company's revenue guidance was to increase by 5% ~ 7% month on month. With the expansion of production capacity, depreciation increased quarter by quarter, and the gross profit margin guidance was between 9% and 11%.

10. Kaineng Health : Subsidiaries of the participating companies have not yet generated operating income in the field of stem cell therapy

kaneng health (300272) disclosed the announcement of abnormal fluctuations in stock trading. the original energy group is a participating enterprise of the company and is not included in the scope of consolidated financial statements. Up to now, in the field of stem cell therapy, Yuantian biological and medical research institutions, a subsidiary of Yuanneng group, are still in the stage of cooperative research and development, and have not yet formed operating income. It is expected that no operating income will be formed in 2024, which will not affect the company's operating performance.